XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma
This is a randomized, multicenter, controlled study to compared the Efficacy and Safety of XELOX combined with Apatinib versus XELOX as post-operative chemotherapy in locally advanced gastric signet ring carcinoma with D2 dissection.
Gastric Carcinoma
DRUG: Apatinib|DRUG: XELOX
Disease Free Survival(DFS), Disease Free Survivalof the Participants, 5 years
Overall Survival(OS), Overall Survival of the Participants, 8 years|Percentage of Participants With Adverse Events, Percentage of Participants With Adverse Events, 5 years
The purpose of this study is to prove that as for disease free survival time, and safety, Apatinib with XELOX(Oxaliplatin with Capecitabine) has a better effect over that of XELOX adjunct therapy group for postoperative chemotherapy of locally advanced gastric signet ring carcinoma with D2 dissection.